Mar Drugs, 2018, 16(4)

Makaluvamine G from the Marine Sponge Zyzzia fuliginosa Inhibits Muscle nAChR by Binding at the Orthosteric and Allosteric Sites

Although a plethora of such molecules exists in the market, there is still a need for new drugs with rapid on/off-set, increased selectivity, and so forth. We found that pyrroloiminoquinone alkaloid Makaluvamine G (MG) inhibits several subtypes of nicotinic receptors and ionotropic γ-aminobutiric acid receptors, showing a higher affinity and moderate selectivity toward muscle nAChR. The action of MG on the latter was studied by a combination of electrophysiology, radioligand assay, fluorescent microscopy, and computer modeling. MG reveals a combination of competitive and un-competitive inhibition and caused an increase in the apparent desensitization rate of the murine muscle nAChR. Modeling ion channel kinetics provided evidence for MG binding in both orthosteric and allosteric sites. We also demonstrated that theα1 (G153S) mutant of the receptor, associated with the myasthenic syndrome, is more prone to inhibition by MG. Thus, MG appears to be a perspective hit molecule for the design of allosteric drugs targeting muscle nAChR, especially for treating slow-channel congenital myasthenic syndromes.

IBCH: 3082
Ссылка на статью в журнале: http://www.mdpi.com/1660-3397/16/4/109
Кол-во цитирований на 08.2024: 8
Данные статьи проверены модераторами 2018-04-01

Список научных проектов, где отмечена публикация

  1. Study of the molecular mechanism of the muscle nicotinic receptor inhibition by makaluvamine G (November 15, 2016 — January 11, 2018). Kudryavtsev D.S.. RFBR, 900000 rub..
  2. -Конструирование и синтез пептидов - потенциальных лекарственных средств на основе Ly6 семейства и пептидов Conus (January 6, 2016 — December 31, 2020). Tsetlin V.I.. Grant, RSF.